Compare Cytokinetics Inc (CYTK) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Noble Corporation plc — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Noble Corporation plc trades at $42.36 (market cap $6.73B). The key difference: Cytokinetics Inc is the larger of the two by market cap, and Noble Corporation plc pays a 4.74% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Noble Corporation plc for 26 Days on average.
| CYTK | NE | |
|---|---|---|
Market Cap | $8.62B | $6.73B |
Volume | 2,594,626 | 1,027,635 |
Sector | Health | Energy |
52-Week High | $87.26 | $54.37 |
52-Week Low | $54.76 | $26.70 |
Typical Hold Time | 19 Days | 26 Days |
Enterprise Value | $8.72B | $8.16B |
Dividend Yield | — | 4.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported Q2 2026 EPS of -$1.50, beating expectations, but maintains deeply negative profitability with a net income margin of -1,321.12% for 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy studies and presentations at major medical conferences.
Wall Street sentiment is overwhelmingly bullish with a 97.14% buy rating and a $112.60 consensus price target, signaling strong upside potential. However, high cash burn, substantial losses, and significant debt-to-asset ratio of 81.23% present substantial financial risks. Investment appeal hinges on successful commercialization of its pipeline amid intense competition.
Noble Corporation (NE) trades at $42.15, up 2.88% today, with mixed technical signals showing bearish moving averages but neutral oscillators. Fundamentally, the company reported $3.29B revenue for 2025 with 6.59% net margin, though 2026 projections show declining revenue and profitability. Recent news includes a long-term drilling contract with Tullow in Ghana, providing operational visibility into 2027.
The stock faces headwinds from declining earnings momentum and ongoing legal investigations, offset by positive analyst sentiment with a $52 consensus target representing 23% upside. Key risks include execution challenges in a volatile energy market and potential legal liabilities from the Pomerantz investigation announced September 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
